Diasorin (FTSE MIB: DIA) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new LIAISON PLEX® platform as well as its first panel of ...

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "DiaSorin S.p.A. (DIA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. DiaSorin's immunodiagnostic and ...

Good afternoon, this is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin Full-Year 2023 Results Conference Call. As a reminder, all participants are in listen-only ...

Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin Second Quarter 2024 Results Conference Call. As a reminder, all participants are in ...

Hospital CFOs face mounting pressure to balance quality care with financial sustainability. Traditional respiratory testing often leads to unnecessary costs and administrative burdens. The LIAISON ...